CDX

18.2%

7.8¢ cardiex limited

care to elaborate on ‘LinkedIn movements’ do you mean new...

First 91 Last

Share
Profile

Follow
StealthInvest

1,946 Posts.

566

25/04/23

14:09

Post #: 67442796
Share

Originally posted by Jov88: ↑

Clearance will almost certainly be RX, this was the main focus. It allows for everything discussed so far which is at-home patient monitoring and decentralised trials.

This FDA clearance put the Pulse as the ONLY Blood pressure device that allows physician reimbursement for Full arterial health measurements. The global remote patient monitoring market is set to be $117 Billion by 2025 digital health market $500 billion. Granted not all of this will be cardiovascular however, it's already one of the most important metrics to measure someone's general health (with a blood test). Cardiovascular health is only becoming more important, especially considering scientists are finding more links between it and illnesses/diseases (depression, diabetes, liver disease, dementia, Parkinson's) previously not attributable to the heart.

Cardiovascular disease is the leading cause of death worldwide, accounting for about a third of all deaths. Having the only FDA-cleared and doctor-reimbursement-cleared device in the market transfers into a completely untapped market. Doctors don't have to see patients to help assess their heart health, and they will be able to get better metrics than a visit would get anyway. But the kicker is doctors will be able to charge for monitoring these at-home at-risk patients and getting paid directly from the government as a result. Win for patients and doctors.

Then we have the decentralised clinical trial market. 8 out of the top 10 big pharma already use CDXs SphygmoCor tech in their current trials. However, with the focus on decentralised trials increasing trial participation, more than 10-fold means potentially even more devices than consumer-focused are required to offer trial participants.

Now the obvious risks are associated with the current cash balance and Nasdaq listing but all in all the announcement due tomorrow is a company maker. Sales can and will be able to start almost immediately, and relationships and networks are there and will only grow now CDX actually has an FDA-cleared device.

This is finally where the rubber hits the road for CDX. While there have been delays, anyone watching LinkedIn movements knows that they are building and making some big moves. This is where Craig as the marketing man will really start to impress.

Expand

care to elaborate on ‘LinkedIn movements’ do you mean new company starters who post their job movements?

what searches are you using ?

CDX Price at posting: 33.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

STX

Strike Energy secures $153 million for Perth Basin gas projects

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

EMD

Emyria's Empax Centre chosen for mental health clinical trial

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

BRX

Belararox delineates another porphyry in Argentina at Tambo South

FHE

Frontier Energy achieves key milestone for Waroona energy project

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

There are more pages in this discussion • 56 more messages in this thread...

First 91 Last

Add CDX (ASX) to my watchlist

(20min delay)
Last 7.8¢		Change 0.012(18.2%)		Mkt cap ! $22.94M

Open	High	Low	Value	Volume
6.8¢	7.8¢	6.8¢	$18.41K	249.4K

Buyers (Bids)

No.	Vol.	Price($)
1	16838	7.6¢

Sellers (Offers)

Price($)	Vol.	No.
7.8¢	119999	1

View Market Depth

No.	Vol.	Price($)
1	16838	0.076
1	54800	0.073
2	39745	0.072
2	19000	0.070
1	23231	0.066

Price($)	Vol.	No.
0.078	119999	1
0.080	6800	2
0.082	25000	1
0.100	313111	1
0.105	75000	1

Last trade - 16.10pm 21/06/2024 (20 minute delay)

CDX (ASX) Chart

care to elaborate on ‘LinkedIn movements’ do you mean new...

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Emyria's Empax Centre chosen for mental health clinical trial

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Belararox delineates another porphyry in Argentina at Tambo South

Frontier Energy achieves key milestone for Waroona energy project

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

care to elaborate on ‘LinkedIn movements’ do you mean new...

Top Stories

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Emyria's Empax Centre chosen for mental health clinical trial

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Belararox delineates another porphyry in Argentina at Tambo South

Frontier Energy achieves key milestone for Waroona energy project

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News